Navigation Links
Osteotech's MagniFuse(TM) Technology Used in First U.S. Surgery
Date:10/28/2009

EATONTOWN, N.J., Oct. 28 /PRNewswire-FirstCall/ -- Osteotech, Inc. (Nasdaq: OSTE), a leader in the emerging field of biologic products for regenerative healing, announced today that MagniFuse PC (Posterior Cervical) Bone Graft, a new tissue-based product built upon the Company's proprietary MagniFuse bone graft technology platform, has been used for the first time in a spinal surgery in the United States.

Utilizing MagniFuse PC, Dr. Orin Atlas, an orthopedic spine surgeon and chief of spine surgery at Virtua-Burlington Medical Center in Mt. Holly, New Jersey, performed a posterior cervical fusion. Posterior cervical fusion is a surgical procedure to stop motion between two or more vertebrae that may be causing neck pain or damage to the nerves that extend into the upper extremities. "In using MagniFuse for the first time, I found the product to be unique from a biologic perspective and easy to work with from a surgical placement perspective," commented Dr. Atlas. "MagniFuse required minimal hydration and the self-contained delivery system made it easily conformable to the defect once implanted at the surgical site. This graft has a completely unique delivery system and is unlike any other product on the market."

"Over the past 12 months we have worked diligently to prepare our MagniFuse product family for commercialization," said Sam Owusu-Akyaw, Osteotech's President and Chief Executive Officer. "As we have continued to develop MagniFuse, we have incorporated feedback from surgeons that has allowed us to hone the procedure-specific characteristics and clinical utility of the initial new products we are bringing to the spine market. We believe our MagniFuse products will solve many of the implantation challenges that are inherent to both particle- and viscous-based bone graft products such as existing growth factor, stem cell and premium synthetic products. Additionally, based upon its ease-of-use, unique delivery and containment characteristics, MagniFuse products may enable surgeons to advance their grafting techniques."

MagniFuse, which has received clearance from the United States Food and Drug Administration, is Osteotech's new, patented bone graft technology platform that supports a family of products utilized when injury or disease creates a need for bone fusion or new bone growth. The MagniFuse technology platform has a number of distinguishing characteristics:

  • Delivered in a unique, resorbable self-contained delivery system, MagniFuse products provide an optimized scaffold that creates a highly exposed surface area comprised of 100% bone material that is shaped and oriented to provide guided bone healing and that may encourage stronger and more rapid mature bone formation.
  • Based upon Osteotech's proprietary processing and manufacturing technologies, MagniFuse's patented formulation is derived from allograft source material that contains a higher concentration of multiple natural human growth factors.
  • MagniFuse's self-contained delivery system also allows for targeted bone formation because it reduces graft site migration once implanted.
  • MagniFuse is also visible in radiographs, thus providing evidence of its proper placement post-surgery.

These characteristics and others solve many of the challenges associated with currently marketed products including stem cells, growth factors and premium synthetics.

"Based upon current pricing of products in our competitive landscape, we believe MagniFuse products may offer economic benefits that will be of interest to hospital administrators and surgeons," continued Mr. Owusu-Akyaw. "We are very excited to begin the first phase of our strategic launch of MagniFuse, during which we will begin to collect data on the human clinical experiences that we believe will further validate our scientific approach and therapeutic efficacy. We would expect to see MagniFuse products utilized in at least 25 procedures by the time of the North American Spine Society meeting in November. Based upon early feedback, we believe the usage curve will continue to increase as we move toward phase two of our launch in 2010."

About Posterior Cervical Fusion

Posterior cervical fusion is a surgical procedure to stop motion between two or more vertebrae caused by segmental instability. Motion between the vertebrae may cause neck pain or damage to the nerves that extend into the upper extremities. In the surgical procedure, two or more vertebrae are allowed to grow together or fuse into one solid mass. In posterior cervical applications, spinal hardware in the form of screws and rods are utilized along with bone graft materials. The need for posterior cervical fusion most often arises from degenerative changes that occur within the intervertebral discs of the cervical spine, but the procedure is also done to stabilize the spine after a fracture or dislocation and to straighten the cervical spine and stop the progression of a spinal deformity.

About Osteotech

Osteotech, Inc., headquartered in Eatontown, New Jersey, is a global leader in providing biologic solutions for regenerative medicine to support surgeons and their patients through the development of innovative therapy-driven products that alleviate pain, promote regenerative and biologic healing and restore function. For further information regarding Osteotech or this press release, please go to Osteotech's website at www.osteotech.com.

Certain statements made throughout this press release that are not historical facts are forward-looking statements (as defined in the Private Securities Litigation Reform Act of 1995) regarding the Company's future plans, objectives and expected performance. Any such forward-looking statements are based on assumptions that the Company believes are reasonable, but are subject to a wide range of risks and uncertainties and, therefore, there can be no assurance that actual results may not differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, the Company's ability to develop and introduce new products, differences in anticipated and actual product and service introduction dates, the ultimate success of those products in the marketplace, the continued acceptance and growth of current products and services, the impact of competitive products and services, the availability of sufficient quantities of suitable donated tissue and the success of cost control and margin improvement efforts. Certain of these factors are detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission. All information in this press release is as of October 28, 2009 and the Company does not intend to update this information.

SOURCE Osteotech, Inc.


'/>"/>
SOURCE Osteotech, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Breast Health is a Year-Round Priority: New Technology Identifies Risk of Breast Cancer in Younger Women
2. Lumenis Introduces Advanced Retinal Laser Delivery Technology at the 2009 American Academy of Ophthalmology Annual Meeting in San Francisco, California, USA
3. Champions Biotechnology, Inc. Signs Exclusive Licensing Agreement with Ramot for TAR-1, a Novel Therapeutic for the Treatment of Cancer
4. MolSofts New Technology Brings Online Publications to Life in Fully Interactive 3D
5. Advanced Health Media Named to Deloittes 2009 Technology Fast 500(TM)
6. New Clinical Studies Demonstrate the Accuracy of Masimo Noninvasive and Continuous Hemoglobin Monitoring Technology
7. VisionCare Implantable Telescope Technology Presentations Featured at Upcoming American Academy of Ophthalmology and Ophthalmology Innovation Summit Meetings
8. Accuray Ranked 155th Fastest Growing Company in North America on Deloittes 2009 Technology Fast 500(TM)
9. e-Zassi.com Provides Industry With Online U.S. FDA Regulatory Calculator for Rapid Medical Device Technology Assessment
10. Oramed Pharmaceuticals was Chosen to Present Results of a GLP-1 Analog Oral Administration Study at the Diabetes Technology Societys Ninth Annual Meeting (November 5-7, 2009; San Francisco, CA)
11. Cambrex Continuous-Flow Microwave-Assisted Organic Synthesis Technology Wins 2009 Silver Innovation Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/18/2017)... , Feb. 17, 2017 Research and Markets has ... report to their offering. ... The report provides separate comprehensive analytics for the US, ... , Asia-Pacific , Latin America , ... period 2015 through 2022. Also, a six-year historic analysis is provided for ...
(Date:2/17/2017)... , Feb. 17, 2017  Ethicon, Inc. today ... Inc., a privately held medical device company that ... Management System, a novel minimally invasive device for ... Torax Medical will enable Ethicon to offer patients ... laparoscopic Nissen fundoplication surgical procedure. 1 ...
(Date:2/17/2017)... , Feb. 17, 2017 Theravance Biopharma, ... or the "Company") today announced the presentation of ... and orally administered pan-Janus kinase (JAK) inhibitor designed ... Congress of the European Crohn,s and Colitis ... reported further data from its completed Phase 1 ...
Breaking Medicine Technology:
(Date:2/20/2017)... TX (PRWEB) , ... February 20, 2017 , ... ... is now offering a full range of emergency dental care at his office, ... and gums. When patients experience dental emergencies, they are at risk for serious ...
(Date:2/20/2017)... ... February 20, 2017 , ... Chuck E. Cheese’s® and Center for Autism and ... at Chuck E. Cheese’s locations throughout New England, New York and New Jersey to ... experience the fun of visiting Chuck E. Cheese’s in a sensory-friendly environment. , ...
(Date:2/20/2017)... ... February 20, 2017 , ... ... Brands to purchase a new ultrasound-enhanced thrombolysis machine, a state-of-the-art device that breaks ... was facilitated by the Pepin Family Foundation. , “We greatly appreciate this gift ...
(Date:2/19/2017)... ... February 19, 2017 , ... Braun Industries will be participating ... Exposition, the event will take place February 23-25, 2017 at the Calvin L. Rampton ... Booth #909 with three new ambulances on display. , “JEMS is ...
(Date:2/19/2017)... ... February 19, 2017 , ... ... in better care, and MEDfx and the Delaware Health Information Network (DHIN) have ... As the nation’s first state-wide health information exchange, DHIN stores and shares real-time ...
Breaking Medicine News(10 mins):